Abbvie ((ABBV)), Genmab (Otc) ((GMAB)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie and Genmab are conducting a Phase 3 clinical trial to evaluate the efficacy and safety of Epcoritamab, a novel treatment for patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL). The trial, titled A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL), aims to determine if Epcoritamab can offer a more effective treatment option compared to standard chemotherapy regimens.
The study is testing Epcoritamab, also known as EPKINLY™ and GEN3013, which is administered as a subcutaneous injection. It is being compared to standard chemotherapy options, including rituximab-based regimens, to assess its potential benefits in treating DLBCL.
This randomized, open-label trial employs a parallel intervention model with no masking, focusing on treatment as its primary purpose. Participants are randomly assigned to receive either Epcoritamab or a standard chemotherapy regimen, with overall survival and progression-free survival as key endpoints.
The study began on January 13, 2021, with an estimated completion date in 2025. The most recent update was submitted on July 29, 2025. These dates are crucial as they guide investors on the timeline for potential results and subsequent market impact.
The outcome of this trial could significantly influence AbbVie and Genmab’s market positions, potentially boosting their stock performance if Epcoritamab proves superior to existing treatments. This development may also affect investor sentiment and competitive dynamics within the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.